NCT05384626: An ongoing trial by Nuvalent Inc.
This trial is ongoing. It must report results 3 years, 4 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT05384626 |
|---|---|
| Title | A Phase 1/2 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 in Patients With Advanced NSCLC and Other Solid Tumors (ALKOVE-1) |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | June 9, 2022 |
| Completion date | Dec. 31, 2027 |
| Required reporting date | Dec. 30, 2028, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Aug. 26, 2025 |
| Days late | None |